IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

SGLT2 Inhibitors in Heart Failure and Diabetes: Dual Benefit or Risk?

Author :- Shreyash Sakleshwar kurund

- **Abstract** :-

SGLT2 inhibitors demonstrate consistent benefits in preventing and treating heart failure in patients with and without type 2 diabetes. These benefits include reduced risk of cardiovascular death or hospitalization for heart failure

- **Key Benefits :-**

- Reduced Heart Failure Risk: SGLT2 inhibitors lower the risk of hospitalization for heart failure in patients with type 2 diabetes.
- Cardiovascular Benefits: They reduce the risk of major adverse cardiac events (MACE) and cardiovascular death.
- Renoprotective Effects: SGLT2 inhibitors slow the progression of chronic kidney disease.

- **Introduction**

- Global burden of diabetes and heart failure
- Historical separation of diabetes and heart failure management
- Emergence of SGLT2 inhibitors beyond glucose control
- Purpose of the study: Assess **dual impact**, explore **clinical trials**, and **risk-benefit balance**

- **Materials and Methods**
- **Type of study**: Systematic literature review / Meta-analysis / Retrospective cohort study
- **Databases**: PubMed, Scopus, ClinicalTrials.gov, etc.
- **Inclusion criteria**: RCTs, cohort studies involving SGLT2 inhibitors and outcomes in HF and/or T2DM
- **Exclusion criteria**: Case reports, non-human studies
- **Parameters assessed**:
  - HbA1c reduction
  - Hospitalization for heart failure (HHF)
  - Cardiovascular death
  - Renal function decline
  - Adverse events (e.g., UTI, ketoacidosis)

Results

- **Glycemic Control**:
  - ↓ HbA1c (0.5–1%)
  - ↓ body weight
  - ↓ blood pressure
- **Cardiovascular Outcomes**:
  - ↓ HHF in patients with and without diabetes
  - ↓ CV mortality
  - Improved LVEF in HFrEF
- **Renal Outcomes**:
  - Slower GFR decline
  - ↓ albuminuria
  - Renal endpoint protection in CREDENCE trial
- **Adverse Effects**:
  - ↑ genital infections
  - Rare cases of **euglycemic DKA**
  - Slight ↑ in dehydration/hypotension in elderly
- **Key Trials Summary Table** (e.g., EMPA-REG, DAPA-HF, CANVAS, DECLARE-TIMI 58)

- **Discussion**

- **Dual mechanism**: Osmotic diuresis + glucose lowering
- **Evidence supports** use in diabetic and non-diabetic HF patients
- **Clinical relevance**: Reduces polypharmacy by addressing both diseases
- Risk-benefit analysis:
  - Benefits outweigh risks in most populations
  - Caution in elderly, renal impairment, or those with history of ketoacidosis
- Comparison with traditional HF drugs (ACE inhibitors, ARBs, beta-blockers)
- Need for **further long-term safety studies**

- **Conclusion**

- SGLT2 inhibitors show **strong dual efficacy** in diabetes and HF
- Manageable side effect profile
- Recommended for integration into standard **cardio-metabolic therapy**
- Calls for **interdisciplinary collaboration** in managing such patients
- SGLT2 inhibitors offer dual benefits in T2DM and HF
- Robust evidence supports their cardiorenal protection
- Risk are manageable with proper patient selection and monitoring

. Drug-Specific Comparison

Drug	FDA Approval	HF Evidence	Unique Features
Empagliflozin	Diabetes, HF	EMPEROR trials	CV & renal benefit
Dapagliflozin	Diabetes, HF	DAPA-HF	HFpEF benefit
Canagliflozin	Diabetes	CREDENCE	Strong renal focus
Sotagliflozin	Diabetes, HF	SOLOIST-WHF	Dual SGLT1/2 inhibition

- **Mechanism of Action**
  - **Inhibition of glucose reabsorption in proximal renal tubules**
  - **Promotes glucosuria → lowers blood glucose**
  - **Additional mechanisms beneficial in HF:**
    - **Natriuresis and osmotic diuresis**
    - **Reduced preload and afterload**
    - **Decreased interstitial volume and blood pressure**
    - **Improved cardiac metabolism and energy efficiency**

- **Clinical Benefits in Type 2 Diabetes**
  - **Glycemic control without hypoglycemia**
  - **Weight loss**
  - **Reduction in HbA1c levels**
  - **Blood pressure lowering**
  - **Cardiovascular outcome trials (e.g., EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58)**

- **Cardiovascular Benefits**
  - **Reduction in hospitalization for heart failure with reduced ejection fraction (HFrEF)**
  - **Some benefit in HF with preserved ejection fraction (HFpEF)**
  - **Trials:**
    - **DAPA-HF (Dapagliflozin)**
    - **EMPEROR-Reduced / EMPEROR-Preserved (Empagliflozin)**
    - **SOLOIST-WHF (Sotagliflozin)**

- **Renal Benefits**
- **Delay in progression of diabetic nephropathy**
- **Reduction in albuminuria**
- **Decreased risk of ESRD (End-Stage Renal Disease)**
- **Key trial: CREDENCE trial (Canagliflozin)**

- **Potential Risks and Adverse Effects**
- **Genitourinary infections (mycotic infections)**
- **Euglycemic diabetic ketoacidosis (EDKA)**
- **Volume depletion, dizziness, hypotension**
- **Amputation risk (associated with canagliflozin – debated)**
- **Bone fractures (early data, now less emphasized)**

- **Use in Non-Diabetic Heart Failure Patients**
- **Emerging data supports use even in patients without diabetes**
- **Benefits seen in HF patients with or without T2DM**
- **Supports expanding indications beyond glycemic control**

- **Guideline Recommendations :-**
- ECS , AHA/ACC: SGLT2 inhibitors as first-line in HFrEF
- ADA 2024 : preferred add on in T2DM with established CVD or CKD
- Integration in heart failure and diabetes care pathway

- **References**
- Use 15–30 references from:
- Clinical trial data (e.g., DAPA-HF, EMPEROR-Reduced)
- Meta-analyses
- Recent guidelines (ADA, ESC, AHA)
- Review articles from **NEJM**, **Lancet**, **Diabetes Care**, etc